RA backs Mede­or’s $57M round as re­searchers fast for­ward to PhI­II

The Bay Area’s fast-grow­ing biotech Mede­or Ther­a­peu­tics has raised $57 mil­lion in a B round to ad­vance its late-stage tech, which might pre­vent the body’s re­jec­tion of or­gan trans­plants.

The round was led by RA Cap­i­tal Man­age­ment, a well-known crossover in­vestor, sig­nal­ing Mede­or Ther­a­peu­tics may be prep­ping for an IPO in the near fu­ture.

The Cal­i­for­nia biotech, found­ed in 2012, is de­vel­op­ing per­son­al­ized cell-based im­munother­a­py that’s de­signed to switch off the body’s im­mune re­sponse to do­nat­ed and trans­plant­ed or­gans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER